vs

Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and Turning Point Brands, Inc. (TPB). Click either name above to swap in a different company.

Turning Point Brands, Inc. is the larger business by last-quarter revenue ($121.0M vs $62.1M, roughly 1.9× Cytek Biosciences, Inc.). Turning Point Brands, Inc. runs the higher net margin — 6.8% vs -70.9%, a 77.7% gap on every dollar of revenue. On growth, Turning Point Brands, Inc. posted the faster year-over-year revenue change (29.2% vs 8.1%). Turning Point Brands, Inc. produced more free cash flow last quarter ($21.5M vs $-1.8M). Over the past eight quarters, Turning Point Brands, Inc.'s revenue compounded faster (20.7% CAGR vs 17.7%).

Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.

Turning Point Australia (TPAUS) is a conservative lobby group based in Australia, affiliated with Turning Point USA but independent of it. Founded by Joel Jammal and first registered in 2023, the group has become active in trying to influence the outcome of the 2026 South Australian state election in March 2026.

CTKB vs TPB — Head-to-Head

Bigger by revenue
TPB
TPB
1.9× larger
TPB
$121.0M
$62.1M
CTKB
Growing faster (revenue YoY)
TPB
TPB
+21.1% gap
TPB
29.2%
8.1%
CTKB
Higher net margin
TPB
TPB
77.7% more per $
TPB
6.8%
-70.9%
CTKB
More free cash flow
TPB
TPB
$23.3M more FCF
TPB
$21.5M
$-1.8M
CTKB
Faster 2-yr revenue CAGR
TPB
TPB
Annualised
TPB
20.7%
17.7%
CTKB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CTKB
CTKB
TPB
TPB
Revenue
$62.1M
$121.0M
Net Profit
$-44.1M
$8.2M
Gross Margin
52.9%
55.9%
Operating Margin
-9.0%
16.5%
Net Margin
-70.9%
6.8%
Revenue YoY
8.1%
29.2%
Net Profit YoY
-557.1%
239.8%
EPS (diluted)
$0.40

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTKB
CTKB
TPB
TPB
Q4 25
$62.1M
$121.0M
Q3 25
$52.3M
$119.0M
Q2 25
$45.6M
$116.6M
Q1 25
$41.5M
$106.4M
Q4 24
$57.5M
$93.7M
Q3 24
$51.5M
$90.7M
Q2 24
$46.6M
$93.2M
Q1 24
$44.9M
$83.1M
Net Profit
CTKB
CTKB
TPB
TPB
Q4 25
$-44.1M
$8.2M
Q3 25
$-5.5M
$21.1M
Q2 25
$-5.6M
$14.5M
Q1 25
$-11.4M
$14.4M
Q4 24
$9.6M
$2.4M
Q3 24
$941.0K
$12.4M
Q2 24
$-10.4M
$13.0M
Q1 24
$-6.2M
$12.0M
Gross Margin
CTKB
CTKB
TPB
TPB
Q4 25
52.9%
55.9%
Q3 25
52.7%
59.2%
Q2 25
52.3%
57.1%
Q1 25
48.6%
56.0%
Q4 24
58.5%
56.0%
Q3 24
56.3%
55.6%
Q2 24
54.6%
54.1%
Q1 24
51.3%
58.2%
Operating Margin
CTKB
CTKB
TPB
TPB
Q4 25
-9.0%
16.5%
Q3 25
-17.6%
21.8%
Q2 25
-23.3%
22.6%
Q1 25
-36.1%
21.8%
Q4 24
5.2%
19.1%
Q3 24
-8.2%
22.9%
Q2 24
-18.3%
24.5%
Q1 24
-23.9%
23.2%
Net Margin
CTKB
CTKB
TPB
TPB
Q4 25
-70.9%
6.8%
Q3 25
-10.5%
17.7%
Q2 25
-12.2%
12.4%
Q1 25
-27.5%
13.5%
Q4 24
16.8%
2.6%
Q3 24
1.8%
13.6%
Q2 24
-22.4%
14.0%
Q1 24
-13.8%
14.5%
EPS (diluted)
CTKB
CTKB
TPB
TPB
Q4 25
$0.40
Q3 25
$1.13
Q2 25
$0.79
Q1 25
$0.79
Q4 24
$0.15
Q3 24
$0.68
Q2 24
$0.68
Q1 24
$0.63

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTKB
CTKB
TPB
TPB
Cash + ST InvestmentsLiquidity on hand
$90.9M
$222.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$341.7M
$372.0M
Total Assets
$461.5M
$763.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTKB
CTKB
TPB
TPB
Q4 25
$90.9M
$222.8M
Q3 25
$93.3M
$201.2M
Q2 25
$75.5M
$109.9M
Q1 25
$95.3M
$99.6M
Q4 24
$98.7M
$48.9M
Q3 24
$162.3M
$33.6M
Q2 24
$177.9M
$142.2M
Q1 24
$168.8M
$130.9M
Stockholders' Equity
CTKB
CTKB
TPB
TPB
Q4 25
$341.7M
$372.0M
Q3 25
$378.6M
$358.2M
Q2 25
$377.6M
$224.8M
Q1 25
$379.6M
$203.4M
Q4 24
$395.7M
$190.4M
Q3 24
$385.5M
$185.7M
Q2 24
$389.1M
$172.8M
Q1 24
$392.6M
$160.0M
Total Assets
CTKB
CTKB
TPB
TPB
Q4 25
$461.5M
$763.8M
Q3 25
$494.9M
$742.8M
Q2 25
$493.3M
$595.8M
Q1 25
$482.6M
$564.6M
Q4 24
$499.5M
$493.4M
Q3 24
$491.2M
$488.0M
Q2 24
$483.7M
$591.6M
Q1 24
$492.1M
$586.3M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTKB
CTKB
TPB
TPB
Operating Cash FlowLast quarter
$-771.0K
$24.9M
Free Cash FlowOCF − Capex
$-1.8M
$21.5M
FCF MarginFCF / Revenue
-2.9%
17.8%
Capex IntensityCapex / Revenue
1.6%
2.8%
Cash ConversionOCF / Net Profit
3.03×
TTM Free Cash FlowTrailing 4 quarters
$-8.8M
$43.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTKB
CTKB
TPB
TPB
Q4 25
$-771.0K
$24.9M
Q3 25
$-3.9M
$3.3M
Q2 25
$108.0K
$11.8M
Q1 25
$-125.0K
$17.4M
Q4 24
$2.0M
$17.7M
Q3 24
$13.2M
$13.2M
Q2 24
$6.2M
$13.4M
Q1 24
$4.0M
$22.6M
Free Cash Flow
CTKB
CTKB
TPB
TPB
Q4 25
$-1.8M
$21.5M
Q3 25
$-4.6M
$-721.0K
Q2 25
$-1.5M
$7.8M
Q1 25
$-974.0K
$15.2M
Q4 24
$1.1M
$16.6M
Q3 24
$12.2M
$12.6M
Q2 24
$5.2M
$10.9M
Q1 24
$3.4M
$22.3M
FCF Margin
CTKB
CTKB
TPB
TPB
Q4 25
-2.9%
17.8%
Q3 25
-8.7%
-0.6%
Q2 25
-3.2%
6.7%
Q1 25
-2.3%
14.3%
Q4 24
1.9%
17.8%
Q3 24
23.7%
13.9%
Q2 24
11.0%
11.7%
Q1 24
7.6%
26.8%
Capex Intensity
CTKB
CTKB
TPB
TPB
Q4 25
1.6%
2.8%
Q3 25
1.3%
3.4%
Q2 25
3.5%
3.4%
Q1 25
2.0%
2.1%
Q4 24
1.6%
1.2%
Q3 24
2.0%
0.7%
Q2 24
2.3%
2.7%
Q1 24
1.3%
0.4%
Cash Conversion
CTKB
CTKB
TPB
TPB
Q4 25
3.03×
Q3 25
0.16×
Q2 25
0.82×
Q1 25
1.21×
Q4 24
0.21×
7.34×
Q3 24
14.05×
1.07×
Q2 24
1.03×
Q1 24
1.89×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTKB
CTKB

Products$46.6M75%
Services$15.5M25%

TPB
TPB

US$111.5M92%
Non Us$9.6M8%

Related Comparisons